1. Second-line FOLFOX chemotherapy for advanced biliary tract cancer – Authors' reply. Issue 7 (July 2021) Authors: Lamarca, Angela; Palmer, Daniel H; Wasan, Harpreet Singh; Ross, Paul J; Ma, Yuk Ting; Arora, Arvind; Falk, Stephen; Gillmore, Roopinder; Wadsley, Jonathan; Patel, Kinnari; Anthoney, Alan; Maraveyas, Anthony; Iveson, Tim; Waters, Justin S; Hobbs, Claire; Barber, Safia; Ryder, W David; Ramage, John... Journal: Lancet oncology Issue: Volume 22:Issue 7(2021) Page Start: e288 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Issue 5 (May 2021) Authors: Lamarca, Angela; Palmer, Daniel H; Wasan, Harpreet Singh; Ross, Paul J; Ma, Yuk Ting; Arora, Arvind; Falk, Stephen; Gillmore, Roopinder; Wadsley, Jonathan; Patel, Kinnari; Anthoney, Alan; Maraveyas, Anthony; Iveson, Tim; Waters, Justin S; Hobbs, Claire; Barber, Safia; Ryder, W David; Ramage, John... Journal: Lancet oncology Issue: Volume 22:Issue 5(2021) Page Start: 690 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗